Scarica l'app Stockscreener
70.61
0.44%
-0.31
Dopo l'orario di chiusura:
70.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$70.92
Aprire:
$70.92
Volume 24 ore:
5.43M
Relative Volume:
1.26
Capitalizzazione di mercato:
$11.00B
Reddito:
$1.21B
Utile/perdita netta:
$109.52M
Rapporto P/E:
101.42
EPS:
0.6962
Flusso di cassa netto:
$269.60M
1 W Prestazione:
-0.06%
1M Prestazione:
+35.81%
6M Prestazione:
+8.55%
1 anno Prestazione:
+37.01%
Intervallo 1D:
$70.54
$70.98
Intervallo di 1 settimana:
$70.54
$71.00
Portata 52W:
$43.20
$72.16
Bio Techne Corp Stock (TECH) Company Profile
Nome
Bio Techne Corp
Settore
Industria
Telefono
612-379-8854
Indirizzo
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
70.61 | 11.05B | 1.21B | 109.52M | 269.60M | 0.6962 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-07-22 | Ripresa | Stephens | Overweight |
| 2025-07-09 | Iniziato | TD Cowen | Buy |
| 2025-05-30 | Iniziato | Wells Fargo | Overweight |
| 2025-04-09 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Iniziato | Evercore ISI | Outperform |
| 2025-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-08 | Iniziato | Scotiabank | Sector Outperform |
| 2024-02-02 | Downgrade | Stifel | Buy → Hold |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-08-28 | Iniziato | William Blair | Outperform |
| 2023-01-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Aggiornamento | Stifel | Hold → Buy |
| 2021-01-25 | Reiterato | The Benchmark Company | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-07-15 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Downgrade | Stifel | Buy → Hold |
| 2020-05-14 | Iniziato | The Benchmark Company | Buy |
| 2020-01-08 | Ripresa | Stephens | Overweight |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-02 | Aggiornamento | Janney | Neutral → Buy |
| 2019-01-14 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-10-17 | Iniziato | Goldman | Neutral |
| 2018-06-15 | Iniziato | Argus | Buy |
| 2017-07-13 | Iniziato | Wells Fargo | Market Perform |
| 2017-02-09 | Iniziato | Citigroup | Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Buy |
| 2016-11-10 | Ripresa | Leerink Partners | Outperform |
| 2015-01-21 | Reiterato | Robert W. Baird | Outperform |
| 2013-09-20 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
Mostra tutto
Bio Techne Corp Borsa (TECH) Ultime notizie
Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Activist investor Ananym urges Bio-Techne to consider selling - MSN
April McClain Delaney Makes Significant Trades in Bio-Techne Corp, C.H. Robinson Worldwide, and Transdigm Group - Investing.com
List of 18 Acquisitions by Bio-Techne (Jul 2026) - Tracxn
Merck KGaA to acquire Bio-Techne in $11.3 billion deal - qz.com
TECH Downgraded by Benchmark -- Rating Changed to Hold - GuruFocus
TECH Downgraded by TD Cowen -- Price Target Raised to $73.00 - GuruFocus
$64.99 support anchors Bio-Techne stock near current levels - Traders Union
Germany’s Merck to acquire Bio-Techne in $11.3 billion deal - MSN
Merck KGaA to acquire U.S.-based Bio-Techne Corp. for $11.3 billion - chemengonline.com
TECH Downgraded by Citigroup -- Rating Changed to Neutral - GuruFocus
German conglomerate Merck buys Minnesota firm Bio-Techne for $11.3B, one of largest deals in state history - Times West Virginian
Is Bio-Techne stock underperforming the S&P 500? - MSN
Germany's Merck to buy Bio-Techne for $73 per share - MSN
Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history - MSN
Germany's Merck to buy Bio-Techne for $11.3 billion - MSN
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal - MSN
Price to sales forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to book forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Merck KGaA Strikes USD 11.3 Billion Bio-Techne Acquisition to Expand Life Sciences Portfolio - Medical Dialogues
Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI
Enterprise value to EBIT forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to earnings forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
TECH Maintained by Baird -- Price Target Raised to $73.00 - GuruFocus
TECH Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion - MSN
Enterprise value to revenue forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Bio-Techne Corporation Actuals & Estimates (NASDAQ:TECH) - TradingView
Merck KGaA’s $11.3 Billion Bet on Bio-Techne Redraws the Map of Life-Science Tools - Oncodaily
Taxation With Representation: Sidley, Paul Weiss, Kirkland - Law360
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH) - PR Newswire
Merck KGaA to acquire Bio-Techne in $11.3bn deal to strengthen life sciences leadership - leadersleague.com
TECH Downgraded by Stephens & Co. -- Price Target Raised to $73. - GuruFocus
Merck KGaA Acquires Bio-Techne Corporation for 11.3 Billion Dollars - HarianBasis.co
Deutsche Bank cuts Bio-Techne stock rating on Merck acquisition By Investing.com - Investing.com Nigeria
Merck KGaA Doubles Down On Life Sciences With $11.3bn Bio-Techne Buyout - Citeline News & Insights
Bio-Techne Corporation (TECH) Merck KGaAM&A CallSlideshow (NASDAQ:TECH) 2026-06-26 - Seeking Alpha
Stephens Downgrades Bio-Techne to Equal Weight From Overweight, Adjusts Price Target to $73 From $68 - marketscreener.com
Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout - Yahoo Finance
Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets - marketscreener.com
Merck's Bio-Techne buyout put Life Sciences sector in focus: top quant-rated stocks - MSN
Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Raises Price Target to $73 From $66 - marketscreener.com
Merck KGaA's Bio-Techne Deal Seems a Strong Fit -- Market Talk - Moomoo
Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $66 - marketscreener.com
Bio-Techne Co Will Be Required To Pay To Merck KGaA Termination Fee Equal To $230.5 Million If Deal Terminated Under Certain CircumstancesSEC Filing - TradingView
Bio-Techne (TECH) Sees Significant Price Surge - GuruFocus
Merck KGaA (MKGAF) Acquires Bio-Techne (TECH) for $73 per Share - GuruFocus
Merck to buy Bio-Techne (NASDAQ: TECH) in $73 per share all-cash deal - Stock Titan
Bio-Techne retention bonuses approved for Kim Kelderman, Jim Hippel - TradingView
Merck Pulls Off Biggest Deal in a Decade With $11.3 Billion Bio-Techne Acquisition - finance.biggo.com
5 Stocks Winning by Double Digits - Insider Monkey
Bio Techne Corp Azioni (TECH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bio Techne Corp Azioni (TECH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | Director |
May 08 '26 |
Sale |
48.28 |
6,636 |
320,386 |
200 |
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):